Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2627764 | 0.86 | ALDH1A1 (0.68) | SMN1; SMN2ALDH1A1LMNACA1CA2 | |
| SCHEMBL760439 | 0.85 | MMP1 (0.67) | SMN1; SMN2ALDH1A1LMNACA1CA2 | |
| SCHEMBL11509059 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1LMNACA1CA2 | |
| SCHEMBL6619767 | 0.84 | MEP1B (0.62) | SMN1; SMN2ALDH1A1LMNACA1CA2 | |
| SCHEMBL7090406 | 0.84 | CA2 (0.73) | SMN1; SMN2ALDH1A1LMNACA1CA2 | |
| SCHEMBL4859243 | 0.84 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1LMNACA1CA2 | |
| SCHEMBL4859251 | 0.84 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1LMNACA1CA2 | |
| SCHEMBL1997197 | 0.84 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1LMNACA1CA2 | |
| SCHEMBL10788040 | 0.83 | MMP1 (0.59) | SMN1; SMN2ALDH1A1LMNAMMP1MMP2 | |
| SCHEMBL10153991 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1LMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| WO-2023018215-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | 주식회사 빌릭스 | 2023-02-16 | — | — | WO | disclosed |
| US-9782370-B2 | Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma | Gongwin Biopharm Holdings Co., Ltd. (KY) | 2017-10-10 | — | — | US | disclosed |
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | GONGWIN BIOPHARM CO., LTD. (TAIWAN) (TW) | 2017-06-22 | — | — | US | disclosed |
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. | 2007-05-03 | — | — | US | disclosed |
| US-5990353-A | DEMETALLIZING AN ARYLSULFONAMIDE ALKALI METAL SALT WITH AN AROMATIC ISOCYANATE COMPOUND IN AT LEAST ONE SOLVENT; USE AS A COLOR DEVELOPER FOR A THERMAL RECORDING MATERIAL WITH IMPROVED OIL RESISTANCE AND NONPLASTICIZED | YAMAMOTO CHEMICALS, INC. (JP) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | ABCD3, CFTR, ADSL | SMN1; SMN2 4396/4885ALDH1A1 1243/4885LMNA 2336/4885 |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | SMN1; SMN2 4080/4885ALDH1A1 437/4885LMNA 3259/4885 |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | SMN1; SMN2 2584/4885ALDH1A1 728/4885LMNA 920/4885 |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, IMPA1, TYMP | SMN1; SMN2 3999/4885ALDH1A1 406/4885LMNA 3075/4885 |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | AP1M1, AP1G1, AP3B1 | SMN1; SMN2 2557/4885ALDH1A1 1652/4885LMNA 4064/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | SMN1; SMN2 1941/4885ALDH1A1 381/4885LMNA 2924/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | SMN1; SMN2 742/4885ALDH1A1 528/4885LMNA 2154/4885 |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | HDAC10, H1-10, H1-0 | SMN1; SMN2 2704/4885ALDH1A1 538/4885LMNA 1477/4885 |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | SMN1; SMN2 3177/4885ALDH1A1 225/4885LMNA 1887/4885 |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | SMN1; SMN2 4080/4885ALDH1A1 437/4885LMNA 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.